HIA
ALNY icon

Harbor Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Harbor Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$243 – 1161
2024
Q2 		$243 Buy
+1
New +$158 ﹤0.01% 1166
2022
Q3 		– Sell
-1
Closed – – 1323
2022
Q2 		$0 Hold
1
– – ﹤0.01% 1334
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1331
2021
Q4 		$0 Buy
+1
New +$186 ﹤0.01% 1301

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbor Investment Advisory's ALNY Position: Q3 2024 in Review

Harbor Investment Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 1 share — an estimated $243 sold.

Harbor Investment Advisory first reported a position in ALNY in Q4 2021 and held it in 4 quarters. The position peaked at $243 in Q2 2024. 566 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Harbor Investment Advisory reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Harbor Investment Advisory sold 1 Alnylam Pharmaceuticals share in Q3 2024, an estimated $243.
  • Harbor Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Harbor Investment Advisory's Alnylam Pharmaceuticals position peaked at $243 in Q2 2024.
  • 566 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Harbor Investment Advisory's 13F filing for Q3 2024, filed 4 Oct 2024.